Patients with Major Depressive Disorder (MDD) Get Earlier Access to a Not-yet-registered Medicine

Mytomorrows logo

Not-yet-registered transdermal MAO inhibitor available via myTomorrows

Amsterdam, the Netherlands, December 20, 2013 / B3C newswire / – The online patient platform myTomorrows will offer patients access to an antidepressant medicine from the UK based company Syntropharma Ltd. It concerns a MAO inhibitor that is continuously released in low dosages via a transdermal patch on the skin. Transdermal MAO inhibitors have been registered and approved for the treatment of MDD in the United States for several years.

Although depression is one of the most expensive medical conditions in healthcare, it remains a very stigmatized an underestimated health issue. People with MDD are severely limited in their social engagement and participation in family life and society. Furthermore they have higher risks of developing additional physical conditions like cardiovascular diseases. The MAO inhibitor that is available via myTomorrows could be an alternative for patients with MDD who don’t respond to existing antidepressants.

Sjaak Vink, CEO of myTomorrows, comments “I’m very pleased that myTomorrows offers patients who suffer from MDD and their Psychiatrists a treatment alternative that could better their daily lives. Family members who also suffer from the effects of this disease shouldn’t be forgotten. Their situation is often underestimated.”

Andrew Gardiner, CEO of Syntropharma Ltd, adds “This agreement with myTomorrows underlines our commitment to create early access to our innovative medicines for patients in need and we’re pleased that patients can actually benefit from our collaboration.”

myTomorrows makes this investigational medicine available within the scope of the existing early access legislation. On Psychiatrist’s request the medicine will be supplied as soon as possible in The Netherlands, Belgium Luxembourg, France, Italy, Germany and Turkey.

Note to the editor
The importance of myTomorrows’ efforts for patients in need is underlined by current evolutions in medicine development and market authorization. Adaptive licensing approaches that allow earlier regulatory approval for new medicines to answer the unmet medical needs of patients are gaining popularity amongst European and United States regulators EMA and FDA.

About myTomorrows
myTomorrows is an online patient platform that is creating freedom of choice for patients with unmet medical needs by offering earlier access to medicines that show promising results during clinical trials, but are not officially registered yet. With the support of their doctors, patients who suffer from cancer, a neurological disorder, a rare disease or a severe depression, can have earlier access to such medicines.
To stay informed about the newest medicines myTomorrows can offer to patients with unmet medical needs and their doctors, please register for the myTomorrows Alert at or visit the website

About Syntropharma Ltd
Syntropharma Ltd is a growing speciality pharmaceutical company, based in the UK, engaged in the development and commercialization of prescription medicines in specifically targeted diseases affecting the Central Nervous System.
Syntropharma has a pipeline of CNS products which have been developed using bespoke platform technologies.


Contact Syntropharma Ltd
Andrew Gardiner
Tel:  +44 845 241 4584
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Contact myTomorrows
Sjaak Vink
Tel: +31 88 525 3888
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.This email address is being protected from spambots. You need JavaScript enabled to view it.

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.